References |
1 |
Dapsone was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
2 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635.
|
3 |
CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
|
4 |
Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
|
5 |
Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
|
6 |
Drug Interactions Flockhart Table
|
7 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
8 |
High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population Clin Sci (Lond). 2009 Oct 26;118(3):187-94. doi: 10.1042/CS20090142.
|